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Mass testing of university students for covid-19
The case for regular PCR testing of all students remains strong
Nicholas J Matheson, 1 , 2 Ben Warne, 1 , 2 Michael P Weekes, 2 , 3 Patrick H Maxwell2 , 3
People can clearly incubate and transmit SARS-CoV-2
in the absence of symptoms.1 Nonetheless, the value
of mass testing (large scale asymptomatic screening
to identify cases) has been contested.2 3 In principle,
isolation of people with pre-symptomatic or
asymptomatic SARS-CoV-2 infection will prevent
further spread. In practice, it is less clear whether
enough infectious people can be identified through
screening to have a quantitatively important effect
on transmission, and whether the direct benefits of
enhanced case ascertainment are outweighed by
direct or indirect costs. The debate is complicated by
anabsence of data from randomised controlled trials,
and controversy about the suitability of lateral flow
tests for this purpose.4 5
Students in higher education are at increased risk of
SARS-CoV-2 infection because of their shared
accommodation, abundant social contacts, low
priority for vaccination, and potential for vaccine
hesitancy.67 At the same time, universities have been
at the forefront of research on covid-19. It is therefore
instructive to consider how these institutions have
sought to control transmission among their students.
As well as promoting vaccination, testing students
with symptoms, and contact tracing, many
universities in the UK and North America have
implementedprogrammes to screen for asymptomatic
and pre-symptomatic cases using weekly or twice
weekly laboratory based PCR tests. Data from these
programmes are now available from institutional
websites, preprints, and peer reviewed publications.
What can they teach us about mass testing for
SARS-CoV-2?
The evidence suggests it is possible to sustain high
levels of adherence to regular, voluntary,
asymptomatic screening using nose and throat
swabs.8 9 University led testing programmes have
been strongly supported by students,8 10 11 providing
reassurance at a time when student mental health
and wellbeing have been severely affected by the
pandemic.8 12
The data also show that mass testing can markedly
increase case ascertainment, including a substantial
proportion of people who have yet to develop
symptoms (pre-symptomatic infection).9 13 -15 During
certain stages of the pandemic, some universities
detected more students with SARS-CoV-2 infection
through asymptomatic screening than through
symptomatic testing.14 -16 Provided these students
are supported to self-isolate, it is reasonable to infer
a substantial reduction in ongoing transmission.
PCR testing seems ideally suited to regular screening
of defined populations, since high test sensitivity
minimises the risk of false negative results and
samples are available for genomic sequencing.17 In
a university context, laboratory and logistical
infrastructure canbeplanned inadvance, turnaround
time minimised, and swab or sample pooling used
to reduce costs and demands on testing capacity,
particularly when incidence is low.9 15 18 False
positive results can often be reduced by a two-step
testing strategy, whereby a positive screening test
result is followed routinely by a confirmatory PCR
test.9 Regular, frequent screening is essential to
ensure that infected people are detected early, while
they are still infectious, so that self-isolation is
justified and effective.
What, then, are the remaining unknowns—and how
can success bemeasured? Evidence about secondary
behavioural changes, which may partially offset the
benefits of enhanced case detection, remains limited.
This is a particular concern for programmes based
on lateral flow tests because false negative results
are more common and good evidence of sustained
adherence to twice weekly home testing is lacking.19
In addition, it is unclear how vaccination will affect
participation in voluntary mass testing. Screening
programmes must therefore monitor both
participation rates (how many people are screened
and how often) and the fraction of all cases
ascertained by mass testing.
Countries with high levels of vaccination are
generally rolling back non-pharmaceutical
interventions designed to limit case numbers such
as social distancing and facemasks.At the same time,
the relative benefits of identifying and isolating
contacts have been reduced, because transmission
rates are lower when index cases or their contacts
have been vaccinated.20 21 Nonetheless, the
emergence of new SARS-CoV-2 variants means that
large outbreaks may still occur in vaccinated
populations.22
Compared with other interventions, asymptomatic
screening offers several advantages. Critically, it is
focused on the identification and isolation of cases
rather than contacts; it need not affect the freedom
of individuals (provided testing is informed and
voluntary); and the costs of each programme are
direct and quantifiable, with few indirect economic
consequences.
As long as pandemic control measures are required,
a strong argument exists for mass testing of
populations at high risk of infection, such as students
in higher education. Faced with spread of the delta
variant, many universities have committed to
continuing their programmes of regular PCR based
screening of asymptomatic students. When
prevalence declines, surveillance testing (regular
screening of a fraction of the relevant population)
1the bmj | BMJ 2021;375:n2388 | doi: 10.1136/bmj.n2388
EDITORIALS
1 Cambridge Institute of Therapeutic
Immunology and Infectious Disease,
Cambridge, UK
2 Cambridge University Hospitals,
Cambridge, UK
3 Cambridge Institute for Medical
Research, Cambridge, UK
Correspondence to: N J Matheson
njm25@cam.ac.uk
Cite this as: BMJ 2021;375:n2388
http://dx.doi.org/10.1136/bmj.n2388
Published: 01 October 2021
and genomic sequencing to identify new variants of concern may
be a proportionate response, and universities will again be ideal
laboratories to test the coherence and effectiveness of these
approaches.
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